J&J Hoping To Position Simeprevir As Top Next-Gen Protease Inhibitor For HCV
This article was originally published in Pharmaceutical Approvals Monthly
The pharma’s Janssen unit recently received notification of priority review from FDA for its protease inhibitor simeprevir NDA; meanwhile, the company waits to see if its compound will be used in combination with Bristol’s daclatasvir or Gilead’s sofosbuvir.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.